Test a reduced transplant plan for older leukemia patients
Part of Blood & lymphatic clinical trials.
This Phase 2 trial studies a “reduced-intensity” transplant plan for people age 55–65 who have certain blood cancers and a suitable donor. It may help older patients get the benefits of a transplant with less treatment burden, but it excludes people with serious organ problems or active infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between ages 55 and 65
- Have a suitable stem-cell donor: a matched sibling, a well-matched unrelated donor (9–10/10), or a half-matched (haplo-identical) donor
- Have one of these diagnoses: AML in remission, or MDS (any stage), or CMML (any stage)
- Be able to give informed consent
- Have liver, kidney, and heart test results that meet study limits
- Not have an active infection at the time of screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This trial studies a gentler (“micro-”) transplant approach for people ages 60–74 with acute myeloid leukemia (AML) who are in remission and cannot safely have the usual stronger transplant conditioning. It may help reduce transplant risks while keeping the leukemia under control.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
Hear when a new Disease-free Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.